Publicacións en colaboración con investigadores/as de University of Michigan Medical School (7)

2024

  1. Clinical outcomes after discontinuing anticoagulant therapy in patients with first unprovoked venous thromboembolism

    Journal of Thrombosis and Haemostasis, Vol. 22, Núm. 8, pp. 2234-2246

2023

  1. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)

    Leukemia

2022

  1. Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy (Nature Medicine, (2022), 28, 3, (557-567), 10.1038/s41591-022-01696-4)

    Nature Medicine

  2. Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy

    Nature Medicine, Vol. 28, Núm. 3, pp. 557-567

2002

  1. Induction of Nod2 in myelomonocytic and intestinal epithelial cells via nuclear factor-κB activation

    Journal of Biological Chemistry, Vol. 277, Núm. 44, pp. 41701-41705

2000

  1. Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-x(L)

    Journal of Experimental Medicine, Vol. 191, Núm. 6, pp. 977-984

1999

  1. Erythropoietin can induce the expression of Bcl-x(L) through Stat5 in erythropoietin-dependent progenitor cell lines

    Journal of Biological Chemistry, Vol. 274, Núm. 32, pp. 22165-22169